v3.22.2.2
Restatement Of Previously Issued Financial Statements
3 Months Ended
Mar. 31, 2022
Accounting Changes and Error Corrections [Abstract]  
Restatement Of Previously Issued Financial Statements

Note 2 — Restatement Of Previously Issued Financial Statements

 

The Company previously accounted for its outstanding Private Warrants as components of equity instead of as derivative liabilities. The warrant agreement governing the Private Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant.

 

The Company’s management re-evaluated the Private Warrants under Accounting Standards Codification (“ASC”) Subtopic 815-40, Contracts in Entity’s Own Equity. ASC Section 815-40-15 addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer’s common stock. Under ASC Section 815-40-15, a warrant is not indexed to the issuer’s common stock if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management’s evaluation, the Company’s audit committee, in consultation with management, concluded that the Company’s Private Warrants are not indexed to the Company’s common stock in the manner contemplated by ASC Section 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares.

 

As a result of the above, the Company should have classified the Private Warrants as derivative liabilities in its previously issued financial statements. Under this accounting treatment, the Company is required to measure the fair value of the Private Warrants at the end of each reporting period and recognize changes in the fair value from the prior period in the Company’s operating results for the current period.

 

The Company’s accounting for the Private Warrants as components of equity instead of as derivative liabilities did not have any effect on the Company’s previously reported cash or investments held in the trust account.

 

The table below summarizes the effects of the restatement on the financial statements for all periods being restated:

 

   As Previously Reported   Adjustments   As Restated 
Condensed Balance Sheets as of March 31, 2022 (unaudited)               
Total Liabilities   4,257,304    67,202    4,324,506 
Accumulated Deficit   (3,229,151)   (67,202)   (3,296,353)
Total Stockholders’ Deficit   (3,225,706)   (67,202)   (3,292,908)
                
Condensed Statement of Changes in Stockholders’ Deficit for the three months ended March 31, 2022 (unaudited)               
Net loss   (202,261)   47,368    (154,893)
Total Stockholders’ Deficit   (3,225,706)   (67,202)   (3,292,908)
                
Condensed Statement of Operations for the three months ended March 31, 2022 (unaudited)               
Net loss   (202,261)   47,368    (154,893)
Change in fair value of warrant liabilities   -    47,367    47,367 
Operating expenses: General and administrative   153,518    (1)   153,517 
                
Condensed Statement of Cash Flows for the three months ended March 31, 2022 (unaudited)               
Net loss   (202,261)   47,368    (154,893)
Change in fair value of warrant liabilities   -    (47,367)   (47,367)